(VIANEWS) – VSE Corporation (VSEC), United Therapeutics Corporation (UTHR), Coca Cola Femsa S.A.B. de C.V. (KOF) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. VSE Corporation (VSEC)
17% sales growth and 8.81% return on equity
VSE Corporation operates as a diversified products and services aftermarket company in the United States. The company operates in three segments: Aviation, Fleet, and Federal and Defense. The Aviation segment provides international parts supply and distribution, supply chain solutions, and component and engine accessory maintenance, repair, and overhaul (MRO) services. This segment serves commercial airlines, regional airlines, cargo transporters, MRO integrators and providers, aviation manufacturers, corporate and private aircraft owners, and fixed-base operators (FBOs). The Fleet segment provides parts supply, inventory management, e-commerce fulfillment, logistics, data management, and other services to assist aftermarket commercial and federal customers. This segment also provides sale of vehicle parts and mission critical supply chain services to support client truck fleets, as well as sustainment solutions and managed inventory services to government and commercial truck fleets. The Federal and Defense segment provides aftermarket refurbishment and sustainment services to extend and maintain the life cycle of military vehicles, ships, and aircraft for the DoD. This segment also provides foreign military sales services, engineering, logistics, maintenance, configuration management, prototyping, technology, and field support services to the DoD, and other customers. In addition, this segment offers energy consulting services and IT solutions to various DoD, federal civilian agencies, and commercial clients. The company also provides vehicle and equipment maintenance and refurbishment, logistics, engineering support, energy services, IT and health care IT solutions, as well as consulting services. VSE Corporation was incorporated in 1959 and is headquartered in Alexandria, Virginia.
Earnings Per Share
As for profitability, VSE Corporation has a trailing twelve months EPS of $3.18.
PE Ratio
VSE Corporation has a trailing twelve months price to earnings ratio of 24.13. Meaning, the purchaser of the share is investing $24.13 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.81%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 28.1%, now sitting on 913.44M for the twelve trailing months.
2. United Therapeutics Corporation (UTHR)
15.1% sales growth and 20.08% return on equity
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhance the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing OreniPro, RemoPro, Tyvaso DPI, Trevyent, Ralinepag, and Aurora-GT to treat PAH; Unexisome to treat bronchopulmonary dysplasia; and the research and development of various organ transplantation-related technologies, including regenerative medicine, xenotransplantation, and ex-vivo lung perfusion, as well as the development of medicine for other diseases. It has licensing and collaboration agreements with Medtronic, Inc. to develop and commercialize the implantable system for Remodulin; Caremark, L.L.C. to provide refills of implanted pumps at its infusion centers; DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of Remodulin; MannKind Corporation to develop and license treprostinil inhalation powder and Dreamboat devices; and Arena Pharmaceuticals, Inc. to develop ralinepag for the treatment of PAH. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
Earnings Per Share
As for profitability, United Therapeutics Corporation has a trailing twelve months EPS of $21.12.
PE Ratio
United Therapeutics Corporation has a trailing twelve months price to earnings ratio of 12.99. Meaning, the purchaser of the share is investing $12.99 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 20.08%.
3. Coca Cola Femsa S.A.B. de C.V. (KOF)
13.3% sales growth and 17.34% return on equity
Coca-Cola FEMSA, S.A.B. de C.V., a franchise bottler, produces, markets, sells, and distributes Coca-Cola trademark beverages. The company offers sparkling beverages, including colas and flavored sparkling beverages; and waters and still beverages, such as juice drinks, coffee, teas, milk, value-added dairy products, sports drinks, energy drinks, and plant-based drinks. It provides a portfolio of products through retail outlets, such as wholesale supermarkets, discount stores, and convenience stores; retailers, such as restaurants and bars, as well as stadiums, auditoriums, and theaters; points-of-sale outlets; and home delivery and other locations. The company also distributes and sells Heineken beer products in its Brazilian territories. It operates in Mexico, Guatemala, Nicaragua, Costa Rica, Panama, Colombia, Brazil, Argentina, and Uruguay. Coca-Cola FEMSA, S.A.B. de C.V. was founded in 1979 and is based in Mexico City, Mexico. Coca-Cola FEMSA, S.A.B. de C.V. is a subsidiary of Fomento Economico Mexicano, S.A.B. de C.V.
Earnings Per Share
As for profitability, Coca Cola Femsa S.A.B. de C.V. has a trailing twelve months EPS of $1.
PE Ratio
Coca Cola Femsa S.A.B. de C.V. has a trailing twelve months price to earnings ratio of 93.2. Meaning, the purchaser of the share is investing $93.2 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.34%.
Moving Average
Coca Cola Femsa S.A.B. de C.V. ‘s value is under its 50-day moving average of $96.78 and higher than its 200-day moving average of $89.72.
Yearly Top and Bottom Value
Coca Cola Femsa S.A.B. de C.V. ‘s stock is valued at $93.20 at 06:22 EST, way below its 52-week high of $104.38 and way higher than its 52-week low of $69.33.
4. Grand Canyon Education (LOPE)
9.7% sales growth and 30.09% return on equity
Grand Canyon Education, Inc. provides education services to colleges and universities in the United States. The company's technology services include learning management system, internal administration, infrastructure, and support services; academic services comprises program and curriculum, faculty and related training and development, class scheduling, and skills and simulation lab sites; and counseling services and support include admission, financial aid, and field experience and other counseling services. It also offers marketing and communication services, such as lead acquisition, digital communications strategy, brand identity, market research, media planning and strategy, video, and business intelligence and data science; and back-office services comprising finance and accounting, human resources, audit, and procurement services. The company supports healthcare education programs for 27 universities. Grand Canyon Education, Inc. was founded in 1949 and is based in Phoenix, Arizona.
Earnings Per Share
As for profitability, Grand Canyon Education has a trailing twelve months EPS of $7.15.
PE Ratio
Grand Canyon Education has a trailing twelve months price to earnings ratio of 20.26. Meaning, the purchaser of the share is investing $20.26 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 30.09%.
